A detailed history of Amalgamated Bank transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Amalgamated Bank holds 1,154 shares of KOD stock, worth $3,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,154
Previous 1,154 -0.0%
Holding current value
$3,069
Previous $6,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$3.01 - $7.45 $5,225 - $12,933
-1,736 Reduced 60.07%
1,154 $6,000
Q4 2023

Feb 06, 2024

SELL
$1.4 - $3.24 $480 - $1,111
-343 Reduced 10.61%
2,890 $9,000
Q2 2023

Aug 11, 2023

SELL
$4.3 - $9.48 $911 - $2,009
-212 Reduced 6.15%
3,233 $22,000
Q1 2023

May 02, 2023

SELL
$4.81 - $8.88 $3,713 - $6,855
-772 Reduced 18.31%
3,445 $21,000
Q2 2022

Aug 15, 2022

SELL
$5.04 - $9.48 $6,229 - $11,717
-1,236 Reduced 22.67%
4,217 $32,000
Q1 2022

Jun 30, 2022

SELL
$7.09 - $89.45 $3,133 - $39,536
-442 Reduced 7.5%
5,453 $42,000
Q4 2021

Feb 15, 2022

SELL
$80.85 - $128.49 $5,174 - $8,223
-64 Reduced 1.07%
5,895 $500,000
Q3 2021

Oct 29, 2021

SELL
$81.97 - $106.94 $30,001 - $39,140
-366 Reduced 5.79%
5,959 $572,000
Q2 2021

Aug 16, 2021

BUY
$77.2 - $126.54 $126,144 - $206,766
1,634 Added 34.83%
6,325 $588,000
Q1 2021

May 13, 2021

SELL
$110.45 - $164.47 $37,442 - $55,755
-339 Reduced 6.74%
4,691 $532,000
Q4 2020

Feb 12, 2021

BUY
$60.78 - $154.03 $33,246 - $84,254
547 Added 12.2%
5,030 $738,000
Q3 2020

Oct 30, 2020

SELL
$45.05 - $59.27 $6,081 - $8,001
-135 Reduced 2.92%
4,483 $265,000
Q2 2020

Aug 10, 2020

SELL
$42.74 - $66.25 $3,461 - $5,366
-81 Reduced 1.72%
4,618 $250,000
Q1 2020

May 13, 2020

BUY
$38.18 - $73.95 $13,782 - $26,695
361 Added 8.32%
4,699 $224,000
Q4 2019

Feb 13, 2020

BUY
$13.9 - $76.65 $60,298 - $332,507
4,338 New
4,338 $312,000

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $138M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.